These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Benign prostatic hyperplasia: pathogenesis and medical therapy. Geller J J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438 [TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and medical treatment of benign prostatic hyperplasia. Geller J Prostate Suppl; 1989; 2():95-104. PubMed ID: 2482776 [TBL] [Abstract][Full Text] [Related]
4. [Current drug therapy of benign prostatic hyperplasia]. Schmidbauer CP; Madersbacher S Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400 [TBL] [Abstract][Full Text] [Related]
6. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy in benign prostatic hyperplasia]. Hauri D Ther Umsch; 1995 Jun; 52(6):378-82. PubMed ID: 7541566 [TBL] [Abstract][Full Text] [Related]
8. [New conservative therapeutic approaches in benign prostatic hyperplasia]. Schulze H; Berges R; Paschold K; Senge T Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777 [TBL] [Abstract][Full Text] [Related]
9. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. Krieg M; Bartsch W; Thomsen M; Voigt KD J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338 [TBL] [Abstract][Full Text] [Related]
10. [Benign hypertrophy of the prostate: which treatment, for whom?]. Schulman C Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895 [TBL] [Abstract][Full Text] [Related]
12. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Seftel A; Rosen R; Kuritzky L Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613 [TBL] [Abstract][Full Text] [Related]
14. Medical management of prostatic diseases. Schlegel PN Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322 [TBL] [Abstract][Full Text] [Related]
15. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Levine AC; Kirschenbaum A; Gabrilove JL Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072 [TBL] [Abstract][Full Text] [Related]
16. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Roehrborn CG BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681 [TBL] [Abstract][Full Text] [Related]
17. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
18. Medical management of benign prostatic hyperplasia: a review. Magoha GA East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007 [TBL] [Abstract][Full Text] [Related]
19. [Novel therapeutics strategies in benign hypertrophy of prostate management]. Roumeguère T Rev Med Brux; 2005 Sep; 26(4):S407-11. PubMed ID: 16240894 [TBL] [Abstract][Full Text] [Related]
20. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. McConnell JD Urol Clin North Am; 1990 Aug; 17(3):661-70. PubMed ID: 1695786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]